STOCK TITAN

Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Vera Therapeutics (NASDAQ: VERA), a biotechnology firm focused on serious immunological diseases, announced participation in the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The company's CEO, Marshall Fordyce, will present on June 4 at 9:00 AM PT (12:00 PM ET). A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days post-event. Vera's lead program, atacicept, targets IgA nephropathy and shows potential for other conditions like lupus nephritis.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a corporate presentation and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference, which is taking place June 1-4, 2021.

Presentation details:

Date:Friday, June 4, 2021
Time:9:00 AM PT (12:00 PM ET)
Presenter:Marshall Fordyce, MD, CEO and Founder of Vera

A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.veratx.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation date.

About Vera Therapeutics
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera’s lead program is atacicept, a fusion protein that is in development for IgA nephropathy, a disease with high unmet medical need and no approved therapies. In addition, Vera is evaluating additional diseases where atacicept’s reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE). For more information please visit www.veratx.com.

Investor Contact:
IR@veratx.com

Media Contact:
Greig Communications, Inc.
Kathy Vincent
(310) 403-8951
kathy@greigcommunications.com

 


FAQ

When will Vera Therapeutics present at the Jefferies Virtual Healthcare Conference?

Vera Therapeutics will present on June 4, 2021, at 9:00 AM PT (12:00 PM ET).

Who is presenting for Vera Therapeutics at the Jefferies Conference?

The presentation will be given by CEO Marshall Fordyce.

How can I watch Vera Therapeutics' presentation at the Jefferies Conference?

A live webcast can be accessed on Vera Therapeutics' investor relations section of their website.

What is the focus of Vera Therapeutics' lead program?

Vera Therapeutics' lead program, atacicept, focuses on treating IgA nephropathy.

What other diseases is Vera Therapeutics evaluating with atacicept?

In addition to IgA nephropathy, Vera is evaluating atacicept for lupus nephritis.

Vera Therapeutics, Inc.

NASDAQ:VERA

VERA Rankings

VERA Latest News

VERA Stock Data

2.65B
58.22M
6.83%
95.11%
10.34%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE